1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Samsung Biologics Enters Manufacturing Deals with European Pharma Company

22 Nov 2024
Admin
News Article

Samsung Biologics Enters Manufacturing Deals with European Pharma Company

Samsung Biologics enters manufacturing deals worth US$ 668 million with European pharma company

Overview

Samsung Biologics, a global contract development and manufacturing organization (CDMO), announced a series of manufacturing deals with a Europe-based pharmaceutical company.

About the Deal

The disclosed deals, worth over USD 668 million combined, will run through December 2031.
The latest agreements bring up the company’s cumulative contract value for this year to more than USD 4 billion.

Words from the CEO: Samsung Biologics

“We are delighted to expand our partnership with the European pharmaceutical company toward our shared commitment to delivering high-quality biopharmaceuticals to patients,” said John Rim, president and CEO of Samsung Biologics.
“As we further expand strategic collaboration with clients worldwide, we also make continued investments in our capabilities and manufacturing technologies.
Our goal is to provide the highest-quality services at every stage and deepen our trusted partnerships.”

Samsung Biologics: Pharma Partners

The company has proactively addressed the evolving needs of clients with a series of significant deals this year, solidifying its customer base across the US, Asia, and Europe.
Samsung Biologics has now partnered with 17 of the world’s top 20 pharmaceutical companies and continues to extend contracts with existing clients to support them in advancing innovative therapies.

Samsung Biologics: Work for Future Portfolio

Samsung Biologics is set to add antibody-drug conjugate (ADC) services to its portfolio, with a dedicated facility to be completed by the end of this year.
The company will provide a range of services, including ADC process development and conjugation, leveraging its comprehensive understanding of biologics and expertise in antibody manufacturing and engineering.
Samsung Biologics will also see the opening of Bio Campus II next year, with Plant 5 on track to be operational in April 2025.

About the company: Samsung Biologics

Samsung Biologics is a fully integrated, end-to-end CDMO service provider offering seamless development and manufacturing solutions from cell line development to final aseptic fill/finish as well as laboratory testing services at every stage for biopharmaceutical products.